Dr. Nathan Wayne Blessing, MD

Dr. Blessing practices at Bascom Palmer Eye Institute in Miami, Florida.

Dr. Blessing's NPI, 1104186808, was assigned on May 29, 2012. Dr. Blessing graduated from OU College of Medicine in 2012. Dr. Blessing holds Florida license ME127118.

Dr. Blessing's primary practice is Bascom Palmer Eye Institute, at 900 NW 17th St, Miami, FL 33136 in Miami-Dade County. The practice phone is (305) 326-6031.

Dr. Blessing's primary practice is Bascom Palmer Eye Institute in Miami, Florida. Dr. Blessing is also affiliated with Sylvester Comprehensive Cancer Center. The medical group on file is University of Miami Health System.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Blessing practices. Vendor and product names are available with a free account.

Ophthalmology is Dr. Blessing's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Blessing is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Dr. Blessing's licenses on file in 2 states: Florida and Oklahoma.

Dmand AI lists conjunctivitis, dry eye, eye infection or inflammation, eyelid inflammation, glaucoma, vision problems and visual impairment and blindness among the conditions Dr. Blessing treats.

CMS data shows 2,586 Medicare services from Dr. Blessing across 14 procedure codes in 2024, for 414 Medicare patients. Medicare paid $125,785 for them.

CMS counts 414 Medicare patients who saw Dr. Blessing in 2024. The largest group is 65 to 74, with 176 patients. 75% of them have high cholesterol, and 72% have high blood pressure. 6% are also on Medicaid. Their average risk score is 1.28, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Blessing's median patient age at 71, with 61% women.

In 2024, Dr. Blessing wrote 491 Medicare Part D claims for 307 patients. 61% of them were for generic drugs. CMS names the drug for 429 of them, across 6 drugs with 11 or more claims each, at $4,354 in total drug cost. In 2023, CMS named 330 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Blessing for performance year 2024, reported as part of a group. Dr. Blessing accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 15 procedures of melanoma (skin cancer) excision by Dr. Blessing, more than 70% of the clinicians it reports for that procedure.

Dmand AI links 19 papers to Dr. Blessing, published from 2008 to 2023. 2020 was the busiest year, with 4. The most frequent topics are Orbit, Biomarkers, Tumor and Diagnosis, Differential. Dr. Blessing has published most often in Ophthalmic Plast Reconstr Surg. Dr. Blessing's most frequent co-authors are Sander R. Dubovy, MD, Andrew J. Rong, MD and David T. Tse, MD.

CMS Open Payments shows 38 general payments to Dr. Blessing from 12 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 52% of the total. Horizon Pharma plc paid the most, $1,905.

Dr. Blessing graduated from OU College of Medicine in 2012. Dr. Blessing is a member of AAO, AMA, American Society of Ophthalmic Plastic and Reconstructive Surgery and Association for Research in Vision and Ophthalmology.

Dr. Blessing is in network with 14 carriers, including Aetna, Excellus BlueCross BlueShield and United Healthcare. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.